Iomab-ACT: A Pilot Study of 131-I Apamistamab (Iomab-B) Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Conditions: B-ALL; DLBCL; B ALL; Dlbcl-Ci; DLBCL Unclassifiable; DLBCL, Nos Genetic Subtypes; DLBCL Activated B-Cell Type; DLBCL Germinal Center B-Cell Type; Diffuse Large B-cell Lymphoma; HGBL; HGBL, Nos Interventions: Drug: 131-I Apamistamab; Biological: CAR T-cell Sponsors: Memorial Sloan Kettering Cancer Center; Actinium Pharmaceuticals Not yet recruiting
Conclusion Low-dose rasburicase is effective and may be an acceptable choice for critically ill children with haematological malignancies.
Publication date: Available online 18 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Vivek Radhakrishnan, Narendra Agrawal, Bhausaheb Bagal, Ishan Patel
Publication date: Available online 18 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ayşe Pınar Öztürk, Başak Koç, Bülent Zülfikar
Relapsed/Refractory multiple myeloma remains a significant clinical challenge despite a wide array of approved therapeutic agents. Immunotherapy offers an advantage in this setting. Chimeric antigen receptor (CAR) modified T-cells have transformed care for patients with hematological malignancies. CAR-T cells targeting CD-19 B-cell lymphoma cells have shown prominent activity in lymphoma and acute lymphoblastic leukemia (ALL). Recently, the CAR-T cell platform for MM demonstrated therapeutic benefit.
The present study aims to evaluate acute complications and survival rates of childhood acute lymphoblastic leukemia (ALL). We assessed 110 patients treated with 'Children's Oncology Group's protocol between 1999 and 2014. Data of 110 patients (65 Male/45 female) and acute complications of 105 patients were recorded. Forty patients were in the standard-risk group, while 70 were in the high-risk group. Infections were the most common type of complications patients (88.5%), followed by gastrointestinal (27.6%), neurological (26.6%), metabolic/endocrine (15.2%), drug-related hypersensitivity (15.2%), avascular necrosis (12.3%)...
This report describes the first systematic literature review of adult acute lymphoblastic leukemia (ALL) practice from India. The literature is scanty and heterogenous with varied institutional incidence rates, male preponderance, B-ALL predominance, and use of different modified non-contemporaneous regimens from developed countries, with reported outcomes of Complete remission (CR), Relapse, and Overall Survival (OS) as 46.7-91.4%, 24.3-57.1%, and 7-46 months, respectively.
Conclusions: As the role and efficacy of autologous HDCT/ABSCT are not established in the analyzed entities, the indication for PBSC collection should be reanalyzed in regular intervals. Moreover, PBSC grafts from patients who have deceased, have insufficient grafts, or have already undergone an allogeneic TPL should be considered for disposal or (if applicable) for research use, to economize storage costs on a rational basis.Transfus Med Hemother
AbstractAimsDiabetes mellitus (DM) is widely recognized as a risk factor for diverse cancers in adults. However, the association between maternal diabetes and risk of childhood cancer in the offspring has so far not been well studied. We thus conducted a meta-analysis to evaluate the role of maternal diabetes on the risk of childhood cancer.MethodsWe performed a comprehensive literature search to identify eligible studies published up to June 20, 2020, including the PubMed, Web of science and Embase databases. Summary odds ratios (OR) and 95% confidence intervals (CI) were computed using a random-effects model (I2 &...
Publication date: Available online 6 August 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Emmanuel Almanza-Huante, Karla Espinosa-Bautista, Juan Rangel-Patiño, Roberta Demichelis-Gómez
Immunotherapy is a very promising therapeutic approach against cancer that is particularly effective when combined with gene therapy. Immuno-gene therapy approaches have led to the approval of four advanced therapy medicinal products (ATMPs) for the treatment of p53-deficient tumors (Gendicine and Imlygic), refractory acute lymphoblastic leukemia (Kymriah) and large B-cell lymphomas (Yescarta). In spite of these remarkable successes, immunotherapy is still associated with severe side effects for CD19+ malignancies and is inefficient for solid tumors. Controlling transgene expression through an externally administered induc...